{
    "organizations": [],
    "uuid": "2b0c9fc4f93bf8c3a797363c432e5ad82b0c9d62",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-karo-pharma-q1-ebitda-rose-to-sek/brief-karo-pharma-q1-ebitda-rose-to-sek-89-mln-idUSASO0003V9",
    "ord_in_thread": 0,
    "title": "Karo Pharma Q1 EBITDA rose to SEK 89 mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - Karo Pharma AB:\n* KARO PHARMA DOUBLES SALES AND EARNINGS IN THE FIRST QUARTER\n* Q1 NET SALES AMOUNTED TO MSEK 267.1 (139.3), EQUIVALENT TO AN INCREASE OF 91.7%\n* Q1 GROSS MARGIN WAS 56.8% (53.7%) FOR PERIOD * Q1 EBITDA AMOUNTED TO MSEK 88.7 (43.7) Source text for Eikon: (Reporting By Stockholm newsroom)\n ",
    "published": "2018-04-26T14:15:00.000+03:00",
    "crawled": "2018-04-27T17:08:17.028+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "karo",
        "pharma",
        "ab",
        "karo",
        "pharma",
        "double",
        "sale",
        "earnings",
        "first",
        "quarter",
        "q1",
        "net",
        "sale",
        "amounted",
        "msek",
        "equivalent",
        "increase",
        "q1",
        "gross",
        "margin",
        "period",
        "q1",
        "ebitda",
        "amounted",
        "msek",
        "source",
        "text",
        "eikon",
        "reporting",
        "stockholm",
        "newsroom"
    ]
}